Pharsight

Drugs that contain Fesoterodine Fumarate

1. Toviaz patents expiration

TOVIAZ Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6858650 PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jul, 2022

(1 year, 8 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6858650

(Pediatric)

PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jan, 2023

(1 year, 2 months ago)

US8501723 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(3 years from now)

US8088398 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(3 years from now)

US7807715 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(3 years from now)

US8501723

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(3 years from now)

US8088398

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(3 years from now)

US7807715

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Jun 17, 2024
Pediatric Exclusivity (PED) Dec 17, 2024

Market Authorisation Date: 31 October, 2008

Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of TOVIAZ before it's drug patent expiration?
More Information on Dosage

TOVIAZ family patents

Family Patents